<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RIFAPENTINE</span><br/>(rif'a-pen-teen)<br/><span class="topboxtradename">Priftin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antituberculosis agent</span><br/><b>Prototype: </b>Rifampin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Rifamycin derivative similar to rifampin. Inhibits DNA-dependent RNA polymerase activity in susceptible bacterial cells, thereby
         suppressing RNA synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by improvement in clinical S&amp;S (e.g., fever, cough, pleuritic pain, fatigue) and on chest x-ray. Inhibits the growth
         of <i>Mycobacterium tuberculosis</i>. Used in conjunction with other antitubercular agents because resistant strains emerge rapidly when employed alone.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Pulmonary tuberculosis in conjunction with at least one other antitubercular agent.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any rifamycins (e.g., rifampin, rifabutin, rifapentine); pregnancy (category C); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with abnormal liver function tests or hepatic disease; HIV disease or concurrent use of protease inhibitors. Safety
         and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tuberculosis: Short-Course Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg twice weekly (at least 72 h apart) times 2 mo, then 600 mg once weekly times 4 mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with an interval of <small>NO LESS</small> than 72 h between doses.
         </li>
<li>Give with food to minimize GI upset.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from excess moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">CV:</span> Hypertension. <span class="typehead">GI:</span> Increased liver function tests (ALT, AST), anorexia, nausea, vomiting, dyspepsia, diarrhea. <span class="typehead">GU:</span> <span class="speceff-common">Hyperuricemia</span>, pyuria, proteinuria, hematuria, urinary casts. <span class="typehead">Hematologic:</span> Neutropenia, lymphopenia, anemia, leukopenia, thrombocytosis. <span class="typehead">Respiratory:</span> Hemoptysis. <span class="typehead">Skin:</span> Rash, pruritus, acne. <span class="typehead"> Body as a Whole:</span> Arthralgia, pain. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Decreased levels of <b>indinavir</b> and possibly other <span class="classification">protease inhibitors</span>; increased metabolism and decreased activity of <span class="classification">oral contraceptives</span>, <b>phenytoin,</b> <b>disopyramide,</b> <b>mexiletine,</b> <b>quinidine,</b> <b>tocainide,</b> <b>warfarin,</b> <b>fluconazole,</b> <b>itraconazole,</b> <b>ketoconazole,</b> <b>diazepam,</b> <span class="classification">beta blockers</span>, <span class="classification">calcium channel blockers</span>, <span class="classification">corticosteroids</span>, <b>haloperidol,</b> <span class="classification">sulfonylureas</span>, <b>cyclosporine,</b> <b>tacrolimus,</b> <b>levothyroxine,</b> <span class="classification">narcotic analgesics</span>, <b>quinine,</b> <span class="classification">reverse transcriptase inhibitors</span>, <span class="classification">tricyclic antidepressants</span>, <b>sildenafil,</b> <b>theophylline.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Approximately 70% absorbed. <span class="typehead">Peak:</span> 56 h. <span class="typehead">Distribution:</span> 97.7% protein bound. <span class="typehead">Metabolism:</span> Hydrolyzed by esterase enzyme to active metabolite in liver; inducer of cytochromes P450 3A4 and 2C8/9. <span class="typehead">Elimination:</span> 70% excreted in feces, 17% in urine. <span class="typehead">Half-Life:</span> 13.3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Sputum smear and culture, CBC, baseline liver functions (especially serum transaminases) to rule out preexisting
            hepatic disease and serum creatinine and BUN.
         </li>
<li>Monitor carefully for S&amp;S of toxicity with concurrent use of oral anticoagulants, digitalis preparations, or anticonvulsants.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Follow strict adherence to the prescribed dosing schedule to prevent emergence of resistant strains of tuberculosis.</li>
<li>Be aware that food may be useful in preventing GI upset.</li>
<li>Report immediately any of the following to the physician: fever, weakness, nausea or vomiting, loss of appetite, dark urine
            or yellowing of eyes or skin, pain or swelling of the joints, severe or persistent diarrhea.
         </li>
<li>Use or add barrier contraceptive if using hormonal contraception.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>